MAPT and Alzheimer disease: The ATN (amyloid β, pathologic tau, and neurodegeneration) biomarkers are currently used for a biological definition of AD, according to the 2018 National Institute on Aging and Alzheimer’s Association (NIA-AA) research framework [3].